News that FDA Commissioner Scott Gottlieb, MD, will step down from his position in 1 month’s time took stakeholders by surprise on Tuesday and raises questions about how the agency will approach biosimilars when it comes under new leadership. While Gottlieb’s departure has garnered the most attention, it is not the only recent FDA shake-up that could have an impact on the agency’s approach to biosimilars; Leah Christl, PhD, previously the director of the Therapeutic Biologics and Biosimilars Staff in the Office of New Drugs, left the FDA in February 2019.
News that FDA Commissioner Scott Gottlieb, MD, will step down from his position in 1 month’s time took stakeholders by surprise on Tuesday and raises questions about how the agency will approach biosimilars when it comes under new leadership.
Throughout his tenure at the FDA, Gottlieb has been vocal about the importance of creating a sustainable biosimilars market in United States. In addition to releasing the Biosimilar Action Plan, he called on drug makers to “end the shenanigans,” including the misuse of Risk Evaluation and Mitigation Strategy programs. He has also taken aim at lengthy patent litigation practices in the United States, pay for delay tactics, and rebates and contracting provisions between pharmacy benefit managers and manufacturers, all of which he said were making the biosimilars market unstable in the United States.
Gottlieb’s approach to biosimilars was seen by many as a sea change; James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, told The Center for Biosimilars® in an interview that Gottlieb represented “a quantum leap in terms of activism.” Shehan said that Gottlieb’s tenure at the FDA compared with those of previous commissioners has been “a pretty stark contrast” in terms of “what he’s done and been willing to do to make the drug market more competitive.”
Biosimilar developers were in harmony with that assessment; the Biosimilars Council, a division of the Association for Accessible Medicines, told The Center for Biosimilars® in an email that a “testament to his commitment to bringing more affordable generic and biosimilar medicines to patients are the record number of approvals seen during his tenure. But [Gottlieb] understood that approvals were not enough to spur competition, and his leadership extended to improving market conditions to ensure these generic and biosimilar medicines would not be blocked.”
The Biosimilars Forum, also in an email to The Center for Biosimilars®, said that “Commissioner Gottlieb has shown strong leadership in both his words and actions to increase access to biosimilars and bring real savings to the US healthcare system…As Congress debates solutions to rising health care costs, it’s been voices like Commissioner Gottlieb’s that are needed to properly highlight the safety, effectiveness and lower costs of these treatments and combat the rampant misinformation that is hurting the US biosimilars market.”
While Gottlieb’s departure has garnered the most attention, it is not the only recent FDA shake-up that could have an impact on the agency’s approach to biosimilars.
Leah Christl, PhD, previously the associate director for therapeutic biologics, director of the therapeutic biologics and biosimilars staff in the office of new drugs in the FDA’s Center for Drug Evaluation and Research, left the FDA in February 2019. Christl, who was replaced at FDA by Sarah Yim, MD, moved to Amgen, reported Regulatory Focus, where she will serve as the drug maker’s executive director of global regulatory and research and development policy beginning on March 11.
During her time at the FDA, Christl was key in facilitating such efforts as developing the agency’s approach to interpreting the Biologics Price Competition and Innovation Act, as well as negotiating and implementing the Biosimilar User Fee Acts.
Christl also frequently served as the face of the agency in communicating about biosimilars; from her “Ask Me Anything” session on biosimilars at the website Reddit to her frequent appearances at biosimilars meetings, Christl was vocal about the need for stakeholder education on biosimilars and the need for the FDA to play an active role in that educational effort.
“It’s not just enough to say, ‘trust us, we got this,’” said Christl in a 2018 presentation on biosimilars. “It’s really important to explain what we’re doing, how we’re doing it, and what we’re looking for in our scientific standards. That then gives people the information to understand the underpinnings of the approval of those products and have confidence that they will be safe and effective products.”
Departure of both Gottlieb and Christl from the agency in short succession raises questions about how ongoing initiatives related to biosimilars will be carried forward under new leadership.
Key projects taken up during Gottlieb and Christl’s tenure include long-awaited and highly anticipated final guidance on interchangeability. Christl had previously indicated that the FDA would issue either revised draft or final guidance no more than 2 years after the end of the comment period on the draft guidance, or May 2019.
Stakeholders are also currently awaiting an agency response to a 2018 citizen petition, filed by Pfizer, asking the FDA to issue guidance on how drug companies may communicate about biosimilars in order to address misinformation about these products.
Other ongoing efforts related to biosimilars include the enhancement of the Purple Book, assessment of the feasibility of using non—US-licensed comparator products in biosimilar development, and coordination with the Federal Trade Commission to address unfair delays to market competition, among others.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.